The DOI matches its Crossref record; 255 of the 255 references it cites were found in a registry or an index.
Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer
Open accessAbstract
BACKGROUND: The TP53 gene is one of the most commonly inactivated tumor suppressors in human cancers. p53 functions during cancer progression have been linked to a variety of transcriptional and non-transcriptional activities that lead to the tight control of cell proliferation, senescence, DNA repair, and cell death. However, converging evidence indicates that p53 also plays a major role in metabolism in both normal and cancer cells. SCOPE OF REVIEW: We provide an overview of the current knowledge on the metabolic activities of wild type (WT) p53 and highlight some of the mechanisms by which p53 contributes to whole body energy homeostasis. We will also pinpoint some evidences suggesting that deregulation of p53-associated metabolic activities leads to human pathologies beyond cancer, including obesity, diabetes, liver, and cardiovascular diseases. MAJOR CONCLUSIONS: p53 is activated when cells are metabolically challenged but the origin, duration, and intensity of these stresses will dictate the outcome of the p53 response. p53 plays pivotal roles both upstream and downstream of several key metabolic regulators and is involved in multiple feedback-loops that ensure proper cellular homeostasis. The physiological roles of p53 in metabolism involve complex mechanisms of regulation implicating both cell autonomous effects as well as autocrine loops. However, the mechanisms by which p53 coordinates metabolism at the organismal level remain poorly understood. Perturbations of p53-regulated metabolic activities contribute to various metabolic disorders and are pivotal during cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53 regulates a series of metabolic diseases, including obesity, diabetes, and fatty liver diseases, through its complicated functions.125,261,262”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [261]
In the citing paper
“Although no clear clinical evidence is available that disordered p53 directly promotes type I diabetes, dysfunctional p53 can induce critical biological processes in diabetes, including disturbances in glucose homeostasis at the organismal level, pancreatic β-cell deficiency, and insulin resistance in peripheral tissues.261”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [261]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–255 of 255
p53 in mitochondria enhances the accuracy of DNA synthesis
Bakhanashvili, M., Grinberg, S., Bonda, E., Simon, A. J., Moshitch-Moshkovitz, S., & Rahav, G. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.122 · Cited by 75
Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis
Dongiovanni, P., Fracanzani, A. L., Cairo, G., Megazzini, C., Gatti, S., Rametta, R., Fargion, S. R., & Valenti, L. V. C. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090249 · Cited by 75
Saletta, F., Rahmanto, Y. S., Noulsri, E., & Richardson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.061028 · Cited by 75
Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis
Prokesch, A., Graef, F. A., Madl, T., Kahlhofer, J., Heidenreich, S., Schumann, A., Moyschewitz, E., Pristoynik, P., Blaschitz, A., Knauer, M., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201600845r · Cited by 75
ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy
Eby, K. G., Rosenbluth, J. M., Mays, D. J., Marshall, C. B., Barton, C. E., Sinha, S., Johnson, K. N., Tang, L., & Pietenpol, J. A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-95 · Cited by 74
Li, X., Cheng, K. K. Y., Liu, Z., Yang, J., Wang, B., Jiang, X. X., Zhou, Y., Hallenborg, P., Hoo, R. L. C., Lam, K. S. L., et al. (2016) · Nature Communications · doi:10.1038/ncomms11740 · Cited by 74
Ceramide Signaling and p53 Pathways
Jeffries, K. A., & Krupenko, N. I. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.04.011 · Cited by 71
p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine
Krstić, J., Galhuber, M., Schulz, T. J., Schupp, M., & Prokesch, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030921 · Cited by 70
Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression
D’Orazi, G., & Cirone, M. (2019) · Cancers · doi:10.3390/cancers11050614 · Cited by 70
Ruiz‐Lozano, P., Hixon, M. L., Wagner, M. W., Flores, A. I., Ikawa, S., Baldwin, A. S., Chien, K. R., & Gualberto, A. (1999) · PubMed · Cited by 69
Hafsi, H., & Hainaut, P. L. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3771 · Cited by 66
TP53 mutation, mitochondria and cancer
Kamp, W. M., Wang, P., & Hwang, P. M. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.02.007 · Cited by 66
p53 tumor suppressor and iron homeostasis
Zhang, J., & Chen, X. (2018) · FEBS Journal · doi:10.1111/febs.14638 · Cited by 66
Silencing of frataxin gene expression triggers p53-dependent apoptosis in human neuron-like cells
Palomo, G. M., Cerrato, T., Gargini, R., & Díaz‐Nido, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr187 · Cited by 65
Wilson, P. M., Fazzone, W., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn910 · Cited by 64
Phenotype Specific Analyses Reveal Distinct Regulatory Mechanism for Chronically Activated p53
Kirschner, K., Samarajiwa, S., Cairns, J., Menon, S., Pérez-Mancera, P. A., Tomimatsu, K., Bermejo‐Rodríguez, C., Ito, Y., Chandra, T., Narita, M., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005053 · Cited by 64
A Novel Antioxidant Function for the Tumor-Suppressor Gene p53 in the Retinal Ganglion Cell
O'Connor, J. C., Wallace, D., O'Brien, C. J., & Cotter, T. G. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-1963 · Cited by 63
Proline dehydrogenase promotes senescence through the generation of reactive oxygen species
Nagano, T., Nakashima, A., Onishi, K., Kawai, K., Awai, Y., Kinugasa, M., Iwasaki, T., Kikkawa, U., & Kamada, S. (2017) · Journal of Cell Science · doi:10.1242/jcs.196469 · Cited by 63
Cam, M., Bid, H. K., Xiao, L., Zambetti, G. P., Houghton, P. J., & Çam, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.530303 · Cited by 62
Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease
Blandino, G., Valenti, F., Sacconi, A., & Agostino, S. D. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.011 · Cited by 62
Ferritin binds and activates p53 under oxidative stress
Lee, J., Jang, H., Cho, E., & Youn, H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.125 · Cited by 61
Burgdorf, K. S., Grarup, N., Justesen, J. M., Harder, M. N., Witte, D. R., Jørgensen, T., Sandbæk, A., Lauritzen, T., Madsbad, S., Hansen, T. F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015813 · Cited by 60
CerS6 Is a Novel Transcriptional Target of p53 Protein Activated by Non-genotoxic Stress
Fekry, B., Jeffries, K. A., Esmaeilniakooshkghazi, A., Ogretmen, B., Krupenko, S. A., & Krupenko, N. I. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.716902 · Cited by 59
Inactivation of arf-bp1 Induces p53 Activation and Diabetic Phenotypes in Mice
Kon, N., Zhong, J., Qiang, L., Accili, D., & Gu, W. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.322867 · Cited by 59
Δ40 Isoform of p53 Controls β-Cell Proliferation and Glucose Homeostasis in Mice
Hinault, C., Kawamori, D., Liew, C. W., Maier, B., Hu, J., Keller, S. R., Mirmira, R. G., Scrable, H. J., & Kulkarni, R. (2011) · Diabetes · doi:10.2337/db09-1379 · Cited by 58
Hua, W.-K., Qi, J., Cai, Q., Carnahan, E., Ayala Ramirez, M., Li, L., Marcucci, G., & Kuo, Y.-H. (2017) · Blood · doi:10.1182/blood-2017-03-771386 · Cited by 57
Wang, S.-J., Yu, G., Jiang, L., Li, T., Lin, Q., Tang, Y., & Gu, W. (2013) · Cell Cycle · doi:10.4161/cc.23597 · Cited by 54
p53 attenuates AKT signaling by modulating membrane phospholipid composition
Rueda-Rincón, N., Bloch, K. M., Derua, R., Vyas, R., Harms, A. C., Hankemeier, T., Khan, N. A., Dehairs, J., Bagadi, M., Binda, M. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4067 · Cited by 53
Naqvi, A., Hoffman, T. A., DeRicco, J. S., Kumar, A., Kim, C., Jung, S.-B., Yamamori, T., Kim, Y., Mehdi, F., Kumar, S., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq331 · Cited by 52
A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH
Kim, H.-R., Roe, J., Lee, J., Hwang, I., Cho, E., & Youn, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.077 · Cited by 43
Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer
Hölzer, K., Drucker, E., Roessler, S. K., Dauch, D., Heinzmann, F., Waldburger, N., Eiteneuer, E. M., Herpel, E., Breuhahn, K., Zender, L., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.09.022 · Cited by 43
P53 suppresses ribonucleotide reductase via inhibiting mTORC1
He, Z., Hu, X., Liu, W., Dorrance, A. M., Garzon, R., Houghton, P. J., & Shen, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17440 · Cited by 43
Hallenborg, P., Fjære, E., Liaset, B., Petersen, R. K., Murano, I., Sonne, S. B., Falkerslev, M., Winther, S., Jensen, B. A. H., Ma, T., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00119.2015 · Cited by 42
Effect of p53 on mitochondrial morphology, import, and assembly in skeletal muscle
Saleem, A., Iqbal, S., Zhang, Y., & Hood, D. A. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00253.2014 · Cited by 40
N’guessan, P., Pouyet, L., Gosset, G., Hamlaoui, S., Seillier, M., Cano, C. E., Seux, M., Stocker, P., Culcasi, M., Iovanna, J., et al. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3553 · Cited by 38
Kirschner, R. D., Rother, K., Müller, G. A., & Engeland, K. (2010) · Cell Cycle · doi:10.4161/cc.9.11.11844 · Cited by 38
Raimondi, I., Ciribilli, Y., Monti, P., Bisio, A., Pollegioni, L., Fronza, G., Inga, A., & Campomenosi, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069152 · Cited by 37
Metabolic pathways regulated by p63
Candi, E., Smirnov, A., Panatta, E., Lena, A. M., Novelli, F., Mancini, M., Viticchiè, G., Piro, M. C., Daniele, N. D., Annicchiarico‐Petruzzelli, M., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.094 · Cited by 37
Role of p53 in preadipocyte differentiation
Huang, Q., Liu, M., Du, X., Zhang, R., Xue, Y., Zhang, Y., Zhu, W., 刘, D. 栋. L., Zhao, A. Z., & Liu, Y. (2014) · Cell Biology International · doi:10.1002/cbin.10334 · Cited by 36
Homayounfar, R., Jeddi‐Tehrani, M., Cheraghpour, M., Ghorbani, A., & Zand, H. (2014) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2014.06.029 · Cited by 36
p53, a novel regulator of lipid metabolism pathways
Goldstein, I., Ezra, O., Rivlin, N., Molchadsky, A., Madar, S., Goldfinger, N., & Rotter, V. (2012) · BMC Proceedings · doi:10.1186/1753-6561-6-s3-p61 · Cited by 36
Porteiro, B., Fondevila, M. F., Buque, X., Gonzalez-Rellan, M. J., Fernandez, U., Mora, A., Beiroa, D., Senra, A., Gallego, R., Fernø, J., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2017.12.005 · Cited by 35
Shimizu, R., Lan, N. N., Tai, T. T., Adachi, Y., Kawazoe, A., Mu, A., & Taketani, S. (2014) · Gene · doi:10.1016/j.gene.2014.08.043 · Cited by 34
Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression
Ortega, F. J., Moreno‐Navarrete, J. M., Mayas, D., Sérino, M., Rodríguez‐Hermosa, J. I., Ricart, W., Luche, É., Burcelin, R., Tinahones, F. J., Frühbeck, G., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.163 · Cited by 31
Gogna, R., Madan, E., Khan, M., Pati, U., & Kuppusamy, P. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202055 · Cited by 29
Promyelocytic Leukemia Protein, a Protein at the Crossroad of Oxidative Stress and Metabolism
Tessier, S., Martín-Martín, N., de Thé, H., Carracedo, A., & Lallemand-Breitenbach, V. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6898 · Cited by 28
Loss of LKB1 in high‐grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53
Co, N. N., Iglesias, D. A., Celestino, J., Kwan, S., Mok, S. C., Schmandt, R. E., & Lu, K. H. (2014) · Cancer · doi:10.1002/cncr.28854 · Cited by 27
Glucose Tolerance in Mice is Linked to the Dose of the p53 Transactivation Domain
Franck, D., Tracy, L., Armata, H. L., Delaney, C. L., Jung, D. Y., Ko, H. J., Ong, H., Kim, J. K., Scrable, H. J., & Sluss, H. K. (2012) · Endocrine Research · doi:10.3109/07435800.2012.735735 · Cited by 27
Secchiero, P., Toffoli, B., Melloni, E., Agnoletto, C., Monasta, L., & Zauli, G. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0476-8 · Cited by 25
Inhibitory effect of p53 on mitochondrial content and function during adipogenesis
Okita, N., Ishikawa, N., Mizunoe, Y., Oku, M., Nagai, W., Suzuki, Y., Matsushima, S., Mikami, K., Okado, H., Sasaki, T., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.059 · Cited by 25
Al–Massadi, O., Porteiro, B., Kuhlow, D., Köhler, M., Gonzalez-Rellan, M. J., García-Lavandeira, M., Díaz‐Rodriguez, E., Quiñones, M., Senra, A., Álvarez, C. V., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1209 · Cited by 25
Guardian of corpulence: a hypothesis on p53 signaling in the fat cell
Bazuine, M., Stenkula, K. G., Cam, M., Arroyo, M., & Cushman, S. W. (2009) · Clinical Lipidology · doi:10.2217/clp.09.2 · Cited by 22
Control of Nucleotide Metabolism Enables Mutant p53’s Oncogenic Gain-of-Function Activity
Schmidt, V. A., Nagar, R., & Martinez, L. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122759 · Cited by 20
Zhang, Y., Zeng, S. X., Hao, Q., & Lu, H. (2017) · Developmental Biology · doi:10.1016/j.ydbio.2017.01.014 · Cited by 17
Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
Kon, N., Wang, D., Li, T., Jiang, L., Qiang, L., & Gu, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23837 · Cited by 17
Cited by
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
Cancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Metadata
- Authors
- Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 33
- Pages
- 2-22
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W2980921743
- Cited by
- 373
- References
- 255
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.